Skip to main content

Table 2 Participant demographics, clinical profile, and use of medication pre treatment

From: Clinical feasibility of cognitive behavioural therapy for insomnia in a real-world mixed sample at a specialized psychiatric outpatient clinic

Variable

Total n = 17

Age, M (range)

47 (20–87)

Sex

 Female, N (%)

11 (65%)

Educational level

 Primary school

1 (6%)

 Secondary school

12 (71%)

 University

4 (24%)

Occupation

 Employed/student

12 (71%)

 Unemployed

3 (18%)

 Retired

3 (18%)

Sick leave (n = 15)a

 100%

2 (12%)

 75%

2 (12%)

 50%

2 (12%)

 25%

3 (18%)

 Not on sick leave

8 (47%)

Psychiatric diagnosis currently treated at the unit

 PTSD

5 (29%)

 Depression or dystyhimia

4 (24%)

 Bipolar disorder 2

3 (18%)

 Bipolar disorder 1

2 (12%)

 Anxiety disorder

2 (12%)

 Other

1 (6%)

Comorbid psychiatric disordersb

 Alcohol and/or substance abuse/addiction

4 (24%)

 ADHD

3 (18%)

 Depression

2 (12%)

 Anxiety disorders

1 (6%)

 Other

1 (6%)

Duration of sleep problems

 Mean years (range)

3 (0.4–10 years)

 0,4-0,9

3 (18%)

 1–2

8 (47%)

 2,1–5

3 (18%)

 5,1–10

3 (18%)

Pre-treatment Insomnia Severity

 Mean ISI score (SD)

19.5 (4.7)

 Clinical insomnia, severe (22–28 points)

5 (29%)

 Clinical insomnia, moderate severity (15–21 points)

10 (59%)

 Sub-threshold insomnia (8–14 points)

2 (12%)

 No clinically significant insomnia (0–7)

0 (0%)

Sleep medications n (%)

 None

1 (6%)

 One type of drug (e.g. antihistamine or z-drug)

9 (53%)

 Two types of drugs (e.g. antihistamine and z-drug)

7 (41%)

Type of sleep medicationc n (%)

 Antihistamines

9 (53%)

 Z-drugs

8 (47%)

 Benzodiazepines

3 (18%)

 Melatonin

1 (6%)

 Propiomazin

1 (6%)

Duration of sleep medication use n (%)

 Mean years (range)

2.9 (0.4–10)

 0,4-0,9

2 (12%)

 1–2

8 (47%)

 2,1–5

3 (18%)

 5,1–10

3 (18%)

Other medications c n (%)

 Antidepressant (SSRI, SNRI, NaSSA, SNRI, NDRI)

13 (76%)

 Lithium

4 (24%)

 Anticonvulsant (e.g. valproat)

3 (18%)

 Stimulants (e.g. methylfenidate)

3 (18%)

 Antipsychotics (e.g. qeutiapin)

3 (18%)

 Opioid substitution drug

1 (6%)

 Benzodiazepines

1 (6%)

  1. apensioners are not included since they can not be on sick leave
  2. bparticapants can have one or several of these diagnoses
  3. cparticapants can use one or several of these drugs